InflaRx (NASDAQ:IFRX) Now Covered by Analysts at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of InflaRx (NASDAQ:IFRX - Free Report) in a report issued on Tuesday morning, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $10.00 price objective on the stock. Cantor Fitzgerald also issued estimates for InflaRx's FY2025 earnings at ($0.87) EPS.

A number of other research firms have also recently issued reports on IFRX. HC Wainwright reaffirmed a "buy" rating and issued a $8.00 price target on shares of InflaRx in a report on Friday, March 21st. Guggenheim raised their target price on InflaRx from $7.00 to $10.00 and gave the stock a "buy" rating in a research note on Wednesday, March 26th.

InflaRx Stock Down 6.5 %

Shares of InflaRx stock traded down $0.12 during trading on Tuesday, reaching $1.73. The company's stock had a trading volume of 325,163 shares, compared to its average volume of 230,906. InflaRx has a 1-year low of $0.82 and a 1-year high of $2.82. The company has a 50-day simple moving average of $1.20 and a two-hundred day simple moving average of $1.82. The company has a market cap of $116.14 million, a price-to-earnings ratio of -1.60 and a beta of 1.57.

InflaRx (NASDAQ:IFRX - Get Free Report) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.18. InflaRx had a negative return on equity of 65.98% and a negative net margin of 33,362.70%. As a group, analysts anticipate that InflaRx will post -1.04 earnings per share for the current year.

Institutional Trading of InflaRx

Large investors have recently made changes to their positions in the business. Two Sigma Securities LLC acquired a new position in InflaRx during the fourth quarter valued at $28,000. Walleye Capital LLC acquired a new position in shares of InflaRx in the 4th quarter valued at about $51,000. Cubist Systematic Strategies LLC acquired a new position in shares of InflaRx in the 4th quarter valued at about $55,000. Geode Capital Management LLC grew its holdings in InflaRx by 32.8% during the fourth quarter. Geode Capital Management LLC now owns 48,136 shares of the company's stock worth $119,000 after acquiring an additional 11,900 shares during the period. Finally, Commonwealth Equity Services LLC grew its holdings in InflaRx by 20.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company's stock worth $275,000 after acquiring an additional 19,000 shares during the period. 42.39% of the stock is owned by hedge funds and other institutional investors.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.